MedTrace Logo

Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)

NCT05543304 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-02-13

No results posted yet for this study

Summary

As the most common type of primary liver cancer, hepatocellular carcinoma (HCC) has become a big challenge all over the world. Most patients are not available to curative resection when first diagnosed. There are a variety of treatment options for advanced HCC. However, due to the heterogeneity of HCC, the overall response rate (ORR) is not high for systemic therapies. Therefore, appropriate selection of patients who are suitable for individual systemic therapies is important for clinical decision-making.

Conditions

  • Hepatocellular Carcinoma Non-resectable
  • Effect of Drug

Interventions

DIAGNOSTIC_TEST

radiological evaluation

All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhejiang Chinese Medical University

    collaborator OTHER

  • Eastern Hepatobiliary Surgery Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    lead OTHER

Principal Investigators

  • Gang Chen, MD,PhD · First Affiliated Hospital of Wenzhou Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2023-12-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05543304 on ClinicalTrials.gov